The Hebrew University of Jerusalem, Jerusalem 91904, Israel.
Inorg Chem. 2011 Sep 5;50(17):7946-8. doi: 10.1021/ic201296h. Epub 2011 Jul 28.
Salen-titanium(IV) complexes are introduced as a new family of highly efficient antitumor complexes, being the first cytotoxic titanium(IV) complexes of trans labile ligands, as characterized crystallographically. Four complexes with different aromatic substitutions were analyzed, reveling a meaningful effect of the ligand structure on the complex performance. All complexes exhibit high hydrolytic stability, where the labile OAr ligands hydrolyze in a 10% D(2)O solution with t(1/2) ranging from 2 to 11 h. The IC(50) values obtained for three of the salen complexes studied on HT-29 colon and OVCAR-1 ovarian cells demonstrate activity that exceeds those of the known tianium(IV) complexes Cp(2)TiCl(2) and (bzac)(2)Ti(OiPr)(2) and that of cisplatin, where the most active para-chlorinated complex exhibits activity enhancement relative to cisplatin by 10-fold.
Salen-钛(IV)配合物被引入为一类新型高效抗肿瘤配合物,是首例具有反式不稳定配体的细胞毒性钛(IV)配合物,其结构特征已通过晶体学方法确定。对具有不同芳香取代基的四个配合物进行了分析,结果表明配体结构对配合物的性能有显著影响。所有配合物均表现出高水解稳定性,其中不稳定的 OAr 配体在 10% D(2)O 溶液中的水解半衰期(t(1/2))范围为 2 至 11 小时。在所研究的三种 Salen 配合物中,对 HT-29 结肠和 OVCAR-1 卵巢细胞的 IC(50)值表明其活性超过了已知的钛(IV)配合物 Cp(2)TiCl(2)和(bzac)(2)Ti(OiPr)(2)以及顺铂,其中最活跃的对氯取代配合物的活性增强了 10 倍。